image: BIO 2026
Credit: BIO 2026
Cambridge, MA, May 29, 2025 — Insilico Medicine ( “Insilico”, HKEX:3696 ), a clinical-stage, generative AI–driven drug discovery company, today announced the company will showcase its latest advances in AI-driven drug discovery, quantum-enabled research, and clinical development through three featured speaking sessions at the BIO 2026 International Convention on June 22-25 at the San Diego Convention Center.
Led by Alex Zhavoronkov, Ph.D, founder , co-CEO and CBO of Insilico Medicine, the Insilico team will be meeting with biopharma partners, investors, and researchers to explore collaboration opportunities at Booth # 4021. At the event, Insilico will showcase the capabilities of its end-to-end Pharma.AI platform and latest pipeline.
As a recognized leader in generative AI–driven drug discovery, Insilico Medicine will present the following featured BIO 2026 speaking sessions:
-
ADCs, GLP-1s, and Beyond: How China is Impacting the 2026 BD Landscape Jun 22 3:00 PM - 4:00PM at 32AB
-
Quantum Computing in Drug Discovery June 22 4:15PM - 5:15PM at 28ABCDE
-
Strategic Innovation: Building Smarter Pipelines for Challenging Targets June 25 9:00 AM - 10:00 AM at 29AB
The synergy among AI-driven drug design (AIDD), quantum algorithms, and automation labs are becoming the next-gen engine redefining target identification and compound optimization. At the same time, de-risking early science and investments hinges on meticulous program design, early validation strategies, and milestone-driven execution. As a pioneer deeply embedding AI into drug discovery, Insilico Medicine will share unique insights from the intersection of cutting-edge tech and clinical translation.
“BIO 2026 International Convention is a premier event for fostering the collaborations that drive biotech innovation” said Alex Zhavoronkov, PhD, Founder, co-CEO and CBO of Insilico Medicine. “We look forward to engaging with industry leaders and demonstrating how our Pharma.AI platform, LifeStar 2 laboratory and MMAI Gym for Science are accelerating the discovery of novel therapeutics. Our goal is to forge partnerships that will help enable longer, healthier lives for people around the world.”
Since pioneering next-generation AI in drug discovery, Insilico Medicine has built an extensive therapeutic portfolio across a variety of therapeutic areas, rapidly advancing its internal R&D pipeline and setting a new standard for efficiency. While traditional early-stage drug discovery can take 2.5 to 4 years, Insilico has nominated 30 preclinical candidates at an average pace of just 12 to 18 months per program, synthesizing and testing only 60 to 200 molecules each—highlighting the exceptional capabilities of its AI-driven platform.
Among the company's clinical-stage programs, Rentosertib, the world's first AI-discovered novel-mechanism anti-fibrotic candidate, has completed Phase 2a proof-of-concept clinical trial, demonstrating promising efficacy trends and a favorable safety profile. ISM5411, the PHD1/2 inhibitor with best-in-class potential for treating inflammatory bowel disease (IBD) has completed 2 Phase 1 trials, showing good safety and gut-restrictedPK profile. Additionally, three of Insilico's anti-tumor programs have now reached the first-in-patient dosing stage, and interim results are expected to be shared in the near future.
Since founding in 2014, Insilico has published over 200 peer-reviewed papers. Leveraging sustained scientific breakthroughs at the intersection of biotechnology, artificial intelligence, and automation, Insilico ranked Top 100 global corporate institutions in Nature Index's "2025 Research Leaders: global corporate institutions for biological sciences and natural sciences publications".
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com